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Familial clustering of classic Kaposi sarcoma (CKS) is rare 
with, approximately 100 families reported to date. We studied 
2 consanguineous families, 1 Iranian and 1 Israeli, with mul-
tiple cases of adult CKS and without overt underlying immu-
nodeficiency. We performed genome-wide linkage analysis 
and whole-genome sequencing to discover the putative genetic 
cause for predisposition. A 9-kb homozygous intronic deletion 
in RP11-259O2.1 in the Iranian family and 2 homozygous vari-
ants, 1 in SCUBE2 and the other in CDHR5, in the Israeli family 
were identified as possible candidates. The presented variants 
provide a robust starting point for validation in independent 
samples.
Keywords. classic Kaposi sarcoma; CDHR5; genetic 
linkage; genetic predisposition; RP11-259O2.1; SCUBE2; 
whole-genome sequencing.
Kaposi sarcoma (KS) is an inflammatory soft tissue tumor that 
typically presents as purple lesions of skin and mucosa, but it 
can also spread to lymph nodes and other organs. It is caused 
by an infection with Kaposi sarcoma–associated herpesvirus 
(KSHV), also known as human herpesvirus 8 (HHV-8). The 
infection is necessary, albeit not alone sufficient for the onset of 
the disease. Therefore, other contributing factors are required, 
but despite a considerable amount of research, the precise eti-
ology of this complex disease remains poorly understood.
Kaposi sarcoma has 4 widely recognized clinico-
epidemiological subtypes. They are AIDS-associated Kaposi 
sarcoma, which affects individuals with HIV infection, the 
iatrogenic type, which affects patients undergoing immuno-
suppressive therapy, the African endemic type, which is most 
common in parts of Central and Eastern Africa, and classic 
Kaposi sarcoma (CKS), which most often affects elderly males 
of Mediterranean or Eastern European Jewish backgrounds. 
The age of onset is usually >65, and only a fraction of the cases 
are observed in individuals aged <50 [1]. CKS is a slowly pro-
gressing disease, where the lesions occur most often on the lower 
extremities and are prone to enlarge and spread on the skin.
In rare occasions, CKS clusters in families. To date, approxi-
mately 100 families have been reported, and the age of onset is 
often lower than in nonfamilial CKS. Studies on these families 
have demonstrated, for example, association of certain HLA 
haplotypes with the disease [2]; however, contradictory results 
have also been obtained [3]. In addition, different genetic vari-
ants of KSHV, KSHV DNA load, and other contributing infec-
tions have been studied [4].
We here studied 2 large consanguineous families of Middle 
Eastern origin, 1 from Iran (hereafter referred to as KapoIran) 
and the other from Israel (hereafter referred to as KapoIsrael). 
The seroprevalence of KSHV in Israel is 5%–20% [5], and in 
Iran it is approximately 2% among the general population [6]. 
We used genome-wide linkage analysis and whole-genome 
sequencing to identify the possible genetic causes of CKS pre-
disposition in the 2 families.
METHODS
Ethical Considerations
The study was approved by the National Institute for Health and 
Welfare (THL; 151/5.05.00/2017) and the local ethics committee 
(HUS; 408/13/03/03/09). A written and informed consent was 
obtained from the family members before the study.
Study Families
The KapoIran family had 3 affected males in 2 generations 
(IV-1, IV-3, and V-4) (Figure 1A). Only limited background in-
formation on the family and medical histories of the patients 
was available. The affected were all diagnosed at approximately 
40 years of age. To our knowledge, the symptoms were typical 
for CKS; however, a few years after the CKS diagnosis, IV-1 
was also diagnosed with cutaneous T-cell lymphoma. In the 
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KapoIsrael family (Figure 1B), there were 4 affected siblings, 3 
males (IV-3, IV-5, and IV-7) and 1 female (IV-2), though no 
sample was available for 1 of them (IV-5). Their clinical features 
have been reported previously [4]. The family is of Jewish or-
igin and in addition to the affected individuals, positive KSHV 
infection statuses have been established in 7 of the 8 unaffected 
family members (II-1, IV-1, IV-4, IV-6, V-1, V-2, and V-3). 
The diagnosis ages were 53, 45, 41, and 38 for IV-2, IV-3, IV-5, 
and IV-7, respectively. DNA samples of 11 individuals in each 
family were available for the study. Details of the methods are 
described in the Supplementary Methods.
Whole-Genome Sequencing
Two affected family members from both families were whole-
genome-sequenced (KapoIran IV-3, KapoIran V-4, KapoIsrael 
IV-3, and KapoIsrael IV-7). The whole-genome libraries 
were prepared with the Kapa HyperPrep Kit (Roche, Basel, 
Switzerland). Paired-end sequencing with 75 base pair reads was 
performed using Illumina HiSeq4000 (KapoIran) and Illumina 
HiSeq2000 (KapoIsrael) according to the manufacturer’s 
instructions. Key measures of the whole-genome sequencing 
data are presented in Supplementary Table 1.
Linkage Analysis
Linkage analyses were conducted with MERLIN, version 1.1.2. 
The families were analyzed separately, and in both analyses, a 
recessive inheritance model was assumed using a 0.0001 dis-
ease allele frequency and a penetrance of 80%. The available 
KapoIran family members (Supplementary Methods) were 
genotyped using Affymetrix (Thermo Fisher Scientific Inc., 
Santa Clara, CA) Genome-Wide Human SNP Array 6.0 and 
Affymetrix GeneChip Human Mapping 250K Nsp Array. For 
the analysis, the KapoIran family was split in 2 (Supplementary 
Figure 1). In the KapoIsrael family, whole-genome sequencing 
data were used for genome-wide genotyping of the 2 affected 
individuals (IV-3 and IV-7). Variants with a minor allele fre-
quency ≥0.05 in gnomAD (r2.0.1) were genotyped using the 
UnifiedGenotyper tool from the GATK toolkit (version 3.5) 
and used for subsequent linkage analysis.
Candidate Variant Analysis
The candidate variant analysis focused on genetic alterations 
shared by the affected individuals in each family. BasePlayer 
software (version 1.0.2) [7] was used to study the shared ho-
mozygous and compound heterozygous single nucleotide vari-
ants (SNVs) as well as small insertions and deletions (indels). 
Structural variants (SVs), including deletions, tandem dupli-
cations, inversions, and translocations, were identified with 
DELLY, version 0.0.9.
The analysis focused on variants locating within the linkage-
compatible regions and with a minimum supporting read count 
of 4 to take into account the relatively low mean coverage of the 
whole-genome sequencing and to minimize the number of false 
positives. All variants were analyzed visually and quality-wise to 
exclude mapping artefacts. SNVs and small indels with a minor 
allele frequency ≥0.005 were not considered further. Additional 
filtering was performed using different in-house control sets, 
variant databases, and prediction algorithms. The full list of 
control sets is described in the Supplementary Methods. The 
remaining candidate variants were validated, and their segrega-
tion with the disease was studied by polymerase chain reaction 
(PCR) and Sanger sequencing (details in the Supplementary 
Methods).
RESULTS
We used linkage analysis to map the candidate genomic regions po-
tentially harboring susceptibility variants. In the case of KapoIran, 
the focus on genomic areas with positive logarithm of the odds 
(LOD) scores resulted in detection of 2 regions (Supplementary 
Table 2). Because the linkage analysis in the KapoIsrael family was 
based on the genotypes of the 2 affected individuals only, we re-
stricted our analysis to the genomic regions with a positive LOD 
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Figure 1. Pedigrees of the KapoIran (A) and the KapoIsrael (B) families. The gen-
eration number and the individual number in that generation (eg, III-4) identify the 
family members. Black color (square for male, circle for female) indicates the indi-
viduals affected with classic Kaposi sarcoma. Double line marks intrafamilial mar-
riage. Black diagonal line over the symbol marks the deceased. The individuals with 
a sample available are marked with a black dot under their identification as well as 
the seropositivity status (+/-) if known. The KapoIsrael pedigree has previously been 
reported by Guttman-Yassky and colleagues (2004).
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score and ≥5 cM in length, as these regions were more likely to 
harbor the predisposition gene. That resulted in a total of 33 re-
gions (Supplementary Table 2). The longest linkage-compatible 
regions in the KapoIran and KapoIsrael analyses were a 10.5-
Mb (25.5-cM) region in chromosome 5 and a 82-Mb (79-cM) 
region in chromosome 1, respectively. No overlapping chromo-
somal regions were identified in the 2 families. As each family 
had relatively few affected individuals, the maximum LOD scores 
could not reach formal statistical significance (max. LOD, 1.598 
KapoIran and 0.602 KapoIsrael).
To identify the genetic variants located in the candidate re-
gions, we analyzed whole-genome sequences of 2 affected in-
dividuals from both families (KapoIran IV-3, KapoIran V-4, 
KapoIsrael IV-3, and KapoIsrael IV-7). After identifying the 
shared variants among respective individuals, we established 
4 sets of candidate variants: homozygous protein coding, com-
pound heterozygous protein-coding, homozygous noncoding, 
and homozygous structural variants.
After filtering the data using a minor allele frequency 
threshold of 0.005, 39 structural variants and 6 homozygous 
noncoding variants remained in the KapoIran family. No coding 
variants met the criteria. The visual and quality-based evalu-
ation of the SVs excluded all but 1 of them. The 1 remaining 
candidate variant was a homozygous deletion of 9005 base pairs 
between the bases 1 939 257 and 1 948 262 in chromosome 5 
(GRCh37) within the intron of long intergenic noncoding RNA 
gene RP11-259O2.1 (Supplementary Figure 2).
In the KapoIsrael family, there were 10 homozygous protein-
coding, 62 homozygous noncoding, and 201 structural can-
didate variants that located within the linkage-compatible 
regions. Segregation analysis and SV quality analysis excluded 8 
of the protein-coding variants and all SVs. The 2 protein-coding 
variants that remained were c.1489G  >  A (p.Pro497Ser) in 
SCUBE2 (Signal Peptide, CUB Domain and EGF-like Domain 
Containing 2)  and c.2269C  >  T (p. Gly757Ser) in CDHR5 
(Cadherin Related Family Member 5)  (Supplementary Figure 
3). Both were predicted to be either benign or tolerated by 
Polyphen-2 and SIFT, respectively, although the SCUBE2 var-
iant was predicted to be damaging by DANN scoring. For more 
detailed data on the variants, see Supplementary Table 3.
The candidate variants were validated with PCR and Sanger 
sequencing, and they segregated with CKS in the respective 
families (Table 1). Finally, we examined the noncoding variants. 
None of the variants located at any obvious splice site regions 
were subsequently annotated using the ENCODE data of known 
regulatory regions. The noncoding variants that located at rel-
evant ENCODE annotated regions are listed in Supplementary 
Table 4.
DISCUSSION
The etiology of CKS is still poorly understood. According to 
population-based studies, only about 1 in 10 000 KSHV-infected 
individuals develops classic Kaposi sarcoma [1,8–10] which 
suggests that other contributing factors exist besides the KSHV 
infection. The disease is rarely familial, but the existing families 
provide an excellent opportunity for susceptibility studies. In 
previous studies, there has been evidence of genetic suscepti-
bility in CKS. Mutations in genes WAS, IFNGR1, STIM1, and 
TNFRSF4 (OX40) have been found to cause childhood-onset 
CKS (reviewed in [11]). In adult-onset CKS, STAT4 has been 
suggested as a candidate predisposing gene [12]. All of these 
genes have functions in adaptive immunity, more specifically 
in T-cell function.
In this study, we performed a genome-wide candidate var-
iant analysis of 2 families with adult CKS using whole-genome 
sequencing and linkage analysis. Both families were consan-
guineous and of Middle Eastern origin and were compatible 
with a recessive inheritance pattern; however, no overlapping 
candidate genomic regions were identified, suggesting different 
roots for the genetic susceptibility.
In the KapoIran family, the most promising susceptibility 
variant was a homozygous deletion of 9005 base pairs in the in-
tron of long intergenic noncoding RNA (lincRNA) gene RP11-
259O2.1. The deletion was unique to the family, and we did not 
identify even heterozygous carriers of it in any of the control 
individuals studied. Long intergenic noncoding RNAs are long 
noncoding RNAs (lncRNA) located in between protein coding 
genes. Some lncRNAs have been reported to act in carcinogen-
esis either as oncogenes promoting cell proliferation or as tumor 
suppressors [13]. There is also evidence showing that lncRNA 
dysregulation can contribute to a variety of complex human 
diseases, including autoimmune diseases such as autoimmune 
thyroid disease and psoriasis [13]. Additionally, a majority of 
lncRNAs have been shown to be very tissue-specific [14]. Based 
on GTEx expression data, RP11-259O2.1 has the highest expres-
sion in skin and other epithelial cells (Supplementary Figure 4), 
which is intriguing considering that CKS usually forms lesions 
on the skin of the lower limbs.
In the KapoIsrael family, 2 candidate variants emerged. 
Perhaps the most promising is c.1489G  >  A (p.Pro497Ser) in 
SCUBE2. SCUBE2 is a member of a small SCUBE gene family, 
other members being SCUBE1 and SCUBE3. According to some 
studies, SCUBE2 has functions in carcinogenesis by being able 
to inhibit tumor cell growth, invasion, and proliferation [15]. 
It has also been shown to be expressed in vascular endothelial 
cells and to interact with vascular endothelial growth factor 
(VEGF) [16]. Angiogenesis is an important feature in the for-
mation of Kaposi sarcoma lesions, and the tumors overexpress 
VEGF [17]. Based on GTEx data, SCUBE2 is most expressed in 
bladder, prostate, and breast tissues (Supplementary Figure 4).
The other candidate gene CDHR5, also known as Mucin and 
cadherin-like (MUCDHL), is a member of the cadherin super-
family. Members of this family encode Ca2+-dependent mem-
branous glycoproteins that are important in cell–cell adhesions 
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and regulate multiple different processes including cell prolif-
eration and differentiation. CDHR5 has been shown to interact 
with β-catenin and act as a growth inhibitor in colon cancer 
cells [18]. The variant shared by affected family members was 
predicted benign by all prediction programs that we used. 
Based on GTEx data, CDHR5 is most expressed in the intestine 
and liver (Supplementary Figure 4).
We carried out a thorough genome-wide variant analysis in 
2 large Kaposi sarcoma families. We focused on rare genetic 
alterations that were compatible with monogenic recessive 
inheritance, though a possibility remains that the predisposi-
tion is multifactorial or perhaps simply more common in the 
general population. We hypothesized that the 2 families may 
have shared a common genetic predisposition or genetic de-
fect in the same signaling pathway, but this did not seem to be 
the case, and the possible genetic susceptibility in the families 
appears to have different genetic roots. We found 3 plausible 
susceptibility variants that all segregated with CKS in the fam-
ilies. Of these, variants in SCUBE2 and RP11-259O2.1 were the 
most promising due to known functions and expression in the 
target tissues, respectively. The candidate variants identified in 
this study provide a platform for validation in extended sample 
sets. If validated, the findings should provide opportunities for 
prevention and early detection in susceptible individuals as well 
as valuable clues to the molecular etiology of CKS.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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